---
title: "Citi lowers the target price for FANGZHOU JIANKE to 7.5 yuan, stating that its value is severely underestimated"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280245805.md"
description: "Citi has lowered the target price for FANGZHOU JIANKE to HKD 7.5, believing its current value is severely underestimated. It is expected that revenue for the fiscal year 2025 will reach RMB 3.526 billion, with a net profit of RMB 12 million, turning a profit. FANGZHOU plans to focus on talent recruitment, artificial intelligence investment, and expanding medical insurance cooperation in 2026. The rating is \"Buy/High Risk.\""
datetime: "2026-03-24T02:17:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280245805.md)
  - [en](https://longbridge.com/en/news/280245805.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280245805.md)
---

# Citi lowers the target price for FANGZHOU JIANKE to 7.5 yuan, stating that its value is severely underestimated

Citi published a report stating that FANGZHOU JIANKE (06086.HK) is expected to achieve revenue of RMB 3.526 billion in the fiscal year 2025, representing a year-on-year growth of 30%; net profit is projected to be RMB 12 million, reversing from a net loss of RMB 855 million in 2024. Adjusted net profit is expected to grow by 19% year-on-year to RMB 20 million. By the end of 2025, cash and cash equivalents are expected to be RMB 233 million.

The report indicates that in 2026, FANGZHOU plans to focus on three major areas: 1) talent recruitment and team building; 2) accelerating investment in artificial intelligence to enhance user experience and operational efficiency; 3) expanding cooperation with medical insurance and improving product affordability. The bank believes that FANGZHOU is currently severely undervalued, with the current price corresponding to a forecasted price-to-sales ratio of only 0.4 times for 2026. The rating is "Buy/High Risk," with the target price lowered from HKD 8.5 to HKD 7.5

### Related Stocks

- [06086.HK](https://longbridge.com/en/quote/06086.HK.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)

## Related News & Research

- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [3 deeply undervalued stocks you can buy for less than $100 right now](https://longbridge.com/en/news/286802600.md)
- [SNAP changes in 2026: How stricter rules and rising food prices impact millions of American families](https://longbridge.com/en/news/286801784.md)
- [Sugar Prices Slide as ISO Projects a Record Global Crop](https://longbridge.com/en/news/286799062.md)